Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi, Vito de Novellis, Clive P Page, Peter J Barnes, Mario Cazzola
{"title":"Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review.","authors":"Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi, Vito de Novellis, Clive P Page, Peter J Barnes, Mario Cazzola","doi":"10.1080/17460441.2025.2466704","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To understand the mechanisms of COPD and to discover and test new drugs, laboratory animals are essential. However, the complex changes associated with the disease in humans are difficult to fully replicate in animal models.</p><p><strong>Areas covered: </strong>This review examines the most recent literature on animal models of COPD and their implications for drug discovery and development.</p><p><strong>Expert opinion: </strong>Recent advances in animal models have included the introduction of transgenic mice with an increased propensity to develop COPD-associated features, such as emphysema, and animals exposed to relevant environmental agents other than cigarette smoke, such as biomass smoke and other air pollutants. Additionally, other animal species, including zebrafish, pigs, ferrets and non-human primates, are also increasingly being used to gain insights into human COPD. Furthermore, three-dimensional organoids and humanized mouse models are emerging as technologies for evaluating novel therapeutics in more human-like models. However, despite some notable advances, no model developed to date fully captures the heterogeneity and progression of COPD observed in patients. Therefore, further research is needed to develop improved models that incorporate humanized elements in experimental animals that may better predict therapeutic responses in the clinic and accelerate the development of new treatments for this debilitating disease.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2025.2466704","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: To understand the mechanisms of COPD and to discover and test new drugs, laboratory animals are essential. However, the complex changes associated with the disease in humans are difficult to fully replicate in animal models.
Areas covered: This review examines the most recent literature on animal models of COPD and their implications for drug discovery and development.
Expert opinion: Recent advances in animal models have included the introduction of transgenic mice with an increased propensity to develop COPD-associated features, such as emphysema, and animals exposed to relevant environmental agents other than cigarette smoke, such as biomass smoke and other air pollutants. Additionally, other animal species, including zebrafish, pigs, ferrets and non-human primates, are also increasingly being used to gain insights into human COPD. Furthermore, three-dimensional organoids and humanized mouse models are emerging as technologies for evaluating novel therapeutics in more human-like models. However, despite some notable advances, no model developed to date fully captures the heterogeneity and progression of COPD observed in patients. Therefore, further research is needed to develop improved models that incorporate humanized elements in experimental animals that may better predict therapeutic responses in the clinic and accelerate the development of new treatments for this debilitating disease.
期刊介绍:
Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The Editors welcome:
Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology
Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug
The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.